| |
|
|
|
| |
Buy Atazanavir (Reyataz) online
|
|
| |
|
How and where to order Reyataz (Atazanavir) 300 mg capsules online:
| Shop 1: | PHARM X SELLER - 10% discount coupon 918cc60b466a42ba
|
| Shop 2: | MEDS FOR SALE - 5% discount coupon 5OFF
|
| Prices: | from $2.57 per pill
|
| Forms: | Atazanavir Sulfate 300 mg capsules
|
| Quantity: | 30-300 pills
|
| Type: | Atazanavir brand, Atazor brand, Reyataz generic
|
| Payment: | Visa, Mastercard, AmEx, Bitcoin
|
| Delivery: | Regular and express mail service
|
| Shipping: | Worldwide, including USA, UK, Europe, Canada, Australia |
Indications and usage:
Reyataz (Atazanavir Sulfate) is a protease inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and in pediatric patients 3 months and older weighing at least 5 kg.
It is also prescribed for nonoccupational exposure (post-exposure prophylaxis, a preventive medical treatment after a needlestick injury or other potential exposure).
Dosage and administration:
Pretreatment testing: renal laboratory testing should be performed in all patients prior to initiation of Reyataz and continued during treatment with this medication. Hepatic testing should be performed in patients with underlying liver disease prior to initiation of atazanavir and continued during treatment with this drug.
Treatment-naive adults: Reyataz 300 mg with ritonavir 100 mg once daily with food or atazanavir sulfate 400 mg once daily with food.
Treatment-experienced adults: Reyataz 300 mg with ritonavir 100 mg once daily with food.
Pediatric patients: Reyataz capsule dosage is based on body weight not to exceed the adult dose and must be taken with food.
Reyataz oral powder: must be taken with ritonavir and food and should not be used in pediatric patients who weigh less than 5 kg.
Pregnancy: Reyataz 300 mg with ritonavir 100 mg once daily with food, with dosing modifications for some concomitant medications.
Dosing modifications: may be required for concomitant therapy, renal impairment, and hepatic impairment.
Dosage forms and strengths:
Reyataz (Atazanavir Sulfate) capsules 150 mg, 200 mg, 300 mg.
Reyataz (Atazanavir Sulfate) oral powder: 50 mg packet.
Overdosage:
Human experience of acute overdose with Reyataz (Atazanavir Sulfate) capsules is limited. Single doses up to 1200 mg (three times the 400 mg maximum recommended dose) have been taken by healthy subjects without symptomatic untoward effects. A single self-administered overdose of 29.2 g of Reyataz in a patient with HIV-1 infection (73 times the 400-mg recommended dose) was associated with asymptomatic bifascicular block and PR interval prolongation. These events resolved spontaneously. At Reyataz doses resulting in high atazanavir exposures, jaundice due to indirect (unconjugated) hyperbilirubinemia (without associated liver function test changes) or PR interval prolongation may be observed.
Treatment of overdosage with this medication should consist of general supportive measures, including monitoring of vital signs and ECG, and observations of the patient's clinical status. If indicated, elimination of unabsorbed atazanavir should be achieved by emesis or gastric lavage. Administration of activated charcoal may also be used to aid removal of unabsorbed drug. There is no specific antidote for overdose with atazanavir. Since atazanavir is extensively metabolized by the liver and is highly protein bound, dialysis is unlikely to be beneficial in significant removal of this medicine.
Contraindications:
Reyataz is contraindicated in patients with previously demonstrated hypersensitivity (eg, Stevens-Johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of this product.
Coadministration with alfuzosin, amiodarone (if atazanavir sulfate is coadministered with ritonavir), quinidine (if Reyataz is coadministered with ritonavir), triazolam, orally administered midazolam, ergot derivatives, rifampin, irinotecan, lurasidone (if this drug is coadministered with ritonavir), lovastatin, simvastatin, lomitapide, indinavir, cisapride, pimozide, St. John's wort, nevirapine, elbasvir/grazoprevir, glecaprevir/pibrentasvir, and sildenafil when dosed as Revatio.
Warnings and precautions:
Cardiac conduction abnormalities: PR interval prolongation may occur in some patients. ECG monitoring should be considered in patients with preexisting conduction system disease or when administered with other
drugs that may prolong the PR interval.
Severe skin reactions: discontinue if severe rash develops.
Hyperbilirubinemia: most patients experience asymptomatic increases inindirect bilirubin, which is reversible upon discontinuation. Do not dose reduce. If a concomitant transaminase increase occurs, evaluate for
alternative etiologies.
Phenylketonuria: Reyataz oral powder contains phenylalanine which can be harmful to patients with phenylketonuria.
Hepatotoxicity: patients with hepatitis B or C infection are at risk of increased transaminases or hepatic decompensation. Monitor hepatic laboratory tests prior to therapy and during treatment.
Chronic kidney disease has been reported during postmarketing surveillance in patients with HIV-1 infection treated with atazanavir, with or without ritonavir. Consider alternatives in patients at high risk for renal disease or with preexisting renal disease. Monitor renal laboratory tests prior to therapy and during treatment. Consider discontinuation of atazanavir capsules in patients with progressive renal disease.
Nephrolithiasis and cholelithiasis have been reported. Consider temporary interruption or discontinuation.
The concomitant use of Reyataz with ritonavir and certain other medications may result in known or potentially significant drug interactions. Consult the full prescribing information prior to and during treatment for potential drug interactions.
Patients receiving Atazanavir Sulfate (Reyataz) pills may develop new onset or exacerbations of diabetes mellitus/hyperglycemia, immune reconstitution syndrome, and redistribution/accumulation of body fat.
Hemophilia: spontaneous bleeding may occur and additional factor VIII may be required.
Side effects, adverse reactions:
Most common adverse reactions ( >= 2%) are nausea, jaundice/scleral icterus, rash, headache, abdominal pain, vomiting, insomnia, peripheral neurologic symptoms, dizziness, myalgia, diarrhea, depression, and fever.
To report suspected adverse reactions of Reyataz (Atazanavir Sulfate) capsules and oral powder, contact Bristol-Myers Squibb pharmaceutical compamy or your local FDA.
Drug interactions:
Coadministration of Atazanavir (Reyataz) can alter the concentration of other drugs and other drugs may alter the concentration of atazanavir. The potential drug-drug interactions must be considered prior to and during therapy.
Related medications:
Lamivudine (Epivir)
Ziagen tablets 300 mg
Use in specific populations:
Pregnancy: available human and animal data suggest that atazanavir does not increase the risk of major birth defects overall compared to the background rate.
Lactation: breastfeeding is not recommended.
Hepatitis B or C co-infection: monitor liver enzymes.
Renal impairment: Reyataz is not recommended for use in treatment-experienced patients with end-stage renal disease managed with hemodialysis.
Hepatic impairment: This medicine is not recommended in patients with severe hepatic impairment. Atazanavir with ritonavir is not recommended in patients with any degree of hepatic impairment.
Where to buy atazanavir online:
To purchase Reyataz (Atazanavir) 300 mg capsules from reliable online pharmacies and drugstores at low prices please use resources described above on this webpage.
Here is a list of popular medications containing atazanavir as a main active pharmaceutical ingredient; their trade names, forms, doses, companies - manufacturers, distributors, suppliers, researchers and developers:
| Trade name of the drug |
Pharmaceutical forms and doses |
Companies |
| Atavir |
Capsules; Oral; Atazanavir 300 mg |
Meda |
| Atazor |
Capsules; Oral; Atazanavir 100 mg, 150 mg, 200 mg, 300 mg |
Emcure Pharmaceuticals |
| Reyataz |
Capsules; Oral; Atazanavir 100 mg, 150 mg, 200 mg, 300 mgPowder; Oral; Atazanavir 50 mg |
Johnson & JohnsonEthnor |
Copyright © 2010 - 2023 Central Coast HIV/AIDS Services (CCHAS). All rights reserved.
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
|
Check out
our Facebook
page!
Follow
us on Twitter
|
